#Sweden #Lund #Tethis #Lumito #SmartBioSurface

Introduction

In a significant advancement in the field of imaging technology, Lumito AB and Tethis S.p.A. have successfully completed a preliminary proof-of-concept study examining the synergy between Lumito’s unique upconverted nanoparticles (UCNP) imaging system and Tethis' innovative SmartBioSurface® slides. This collaboration signals a promising development in the techniques used to analyze non-adherent cells, a category of cells known for their unique handling challenges in laboratory settings.

The Study's Focus

The study primarily aimed to determine whether Lumito's advanced labelling and imaging methodologies could be effectively utilized with Tethis’ SmartBioSurface® slides. Designed for non-adherent cells, these slides offer rapid and gentle adhesion, simplifying the process of cell analysis. Non-adherent cells, such as certain stem cells and tumor cells, typically resist traditional culturing techniques, making this research particularly relevant.

Positive Outcomes

Lumito and Tethis reported encouraging results from the study, confirming the feasibility of integrating Lumito's imaging technology with the SmartBioSurface® platform. This compatibility opens up new avenues for streamlining workflows where non-adherent cells are critical. As Sanna Wallenborg, CEO of Lumito, commented, the initial findings underscore the viability of merging technologies from both companies, enhancing possibilities for more comprehensive cell analysis.

Potential for Future Applications

Given the initial success, both companies are set to embark on joint marketing initiatives, advocating the combined approach of their technologies. Noteworthy is the growing interest from external researchers eager to explore this methodology in complex research applications. This aspect signifies potential opportunities for further validation and exploration in advanced biomedical contexts, contributing to innovations in laboratory practices.

About Lumito

Lumito specializes in medical technology with a focus on digital tissue imaging. Their patented techniques leverage UCNPs for high-sensitivity imaging, which allows for the precise identification and measurement of protein biomarkers in tissue samples. Their technology is especially beneficial in drug development and digital pathology, helping to refine diagnostic processes and optimize treatment strategies.

About Tethis

Tethis stands at the forefront of life sciences and diagnostics, developing strategies to incorporate liquid biopsy into clinical settings effectively. Their proprietary technology is dedicated to standardizing blood sample preparation, ensuring the quality and integrity of liquid biopsy specimens, crucial for accurate biomarker analysis in cancer management. With innovative tools like the SmartBioSurface® slides, Tethis excels at detecting rare cells and immune cells with exceptional sensitivity.

Conclusion

The collaboration between Lumito and Tethis marks a pivotal moment in the imaging and analysis of non-adherent cells. By merging technologies with complementary strengths, both companies are not only enhancing the capabilities for cell capture and imaging but also expanding the horizons for future research and clinical applications in life sciences. The results from this initial proof-of-concept study lay a strong foundation for potential breakthroughs in the understanding and treatment of various medical conditions, particularly those involving non-adherent cell types.